Treatment of metabolic disorders in equine animals
The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.
1. A method of treating or preventing a metabolic disorder in an equine comprising administering an SGLT2 inhibitor or pharmaceutically acceptable form thereof, wherein said SGLT2 inhibitor or pharmaceutically acceptable form thereof consists of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene, represented by the following formula:
wherein the metabolic disorder is one or more disorders selected from laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome.
2. The method according to claim 1 , wherein the metabolic disorder is a clinical condition or sign associated with insulin resistance or hyperinsulinaemia.
3. The method according to claim 1 , wherein the metabolic disorder is hyperinsulinemia and/or insulin resistance, and wherein said hyperinsulinemia and/or insulin resistance is associated with one or more of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome.
4. The method according to claim 1 , wherein the equine animal is a horse or a pony.
5. The method according to claim 1 , wherein the equine animal is obese and/or exhibits regional adiposity.
6. The method according to claim 1 , wherein the composition comprises a crystalline complex of the SGLT2 inhibitor or pharmaceutically acceptable form thereof and an amino acid, and the amino acid is proline.
7. The method according to claim 1 , wherein the SGLT2 inhibitor or pharmaceutically acceptable form thereof is administered orally or parenterally.
8. The method according to claim 1 , wherein the SGLT2 inhibitor or pharmaceutically acceptable form thereof is administered orally.
9. The method according to claim 1 , wherein the SGLT2 inhibitor or pharmaceutically acceptable form thereof is administered in a range of from 0.01 to 5 mg/kg body weight per day.
10. The method according to claim 1 , wherein the SGLT2 inhibitor or pharmaceutically acceptable form thereof is administered in a range of from 0.02 to 1.0 mg/kg body weight per day.
11. The method according to claim 1 , wherein the SGLT2 inhibitor or pharmaceutically acceptable form thereof is administered in a range of from 0.03 to 0.4 mg/kg body weight per day.
12. The method according to claim 1 , wherein the SGLT2 inhibitor or pharmaceutically acceptable form thereof is administered once per day.
13. The method according to claim 1 , wherein the equine animal is not obese and/or is present with muscle wasting and/or exhibits hyperglycemia.
14. The method of claim 1 , wherein the composition comprises a 1:1:1 crystalline complex of the SGLT2 inhibitor or pharmaceutically acceptable form thereof, L-proline and water in a crystalline form.
15. The method according to claim 14 , wherein the 1:1:1 crystalline complex is characterized by an X-ray powder diffraction pattern that comprises peaks at 20.28, 21.14 and 21.64 degrees 2Θ (±0.1 degrees 2Θ), wherein said X-ray powder diffraction pattern is made using CuK α1 radiation.
16. The method of claim 1 , wherein said laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome is associated with insulin resistance and/or hyperinsulinemia.